<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39456932</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11149</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms252011149</ELocationID><Abstract><AbstractText>Rheumatoid arthritis (RA) patients face different health challenges when infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than the general population, due to both their immunocompromised state and the immunosuppressive therapies they receive. This systematic literature review, which follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) paradigm, explores the interactions between RA and SARS-CoV-2 infection, focusing on immunologic issues, disease management, vaccination, and adverse outcomes. In order to obtain the most relevant information, we systematically reviewed the specific literature from 1 January 2021 to 31 December 2023, based on the PRISMA method, by which we eventually selected 35 eligible articles, to which we added other ISI-indexed studies to enrich our results further. Consequently, we performed a funnel analysis to evaluate the potential for publication bias. Firstly, the data collected revealed the impact of the pandemic on RA diagnoses and the fear of face-to-face medical consultations that delayed adequate treatment. Secondly, cardiovascular and metabolic comorbidities increase the risk of prolonged COVID-19 symptoms, hospitalization, and severe COVID-19 outcomes for RA patients. With respect to immunosuppressive treatment used to control RA, it was observed that glucocorticoids (especially high-dose usage) and Rituximab (RTX) predispose the patients to poor SARS-CoV-2 outcomes, as opposed to Baricitinib and interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) inhibitors. COVID-19 vaccination has proven effective and generally safe for RA patients in some studies, although therapies with Methotrexate (MTX), Abatacept (ABA), and RTX have been associated with impaired vaccine immune response. This systematic literature review brings updated and thorough information with respect to the immunological, clinical, and management of a complex immune-mediated inflammatory disease (IMID) like RA in the setting of COVID-19 and underlines the challenges faced by this group of patients. The lessons learned can be extended beyond the pandemic in shaping a more informed and compassionate healthcare system and offering long-term medical care for patients with RA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vlădulescu-Trandafir</LastName><ForeName>Andreea-Iulia</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0003-1369-3873</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bojincă</LastName><ForeName>Violeta-Claudia</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine and Rheumatology Departments, "Sfânta Maria" Hospital, 011172 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munteanu</LastName><ForeName>Constantin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1084-7710</Identifier><AffiliationInfo><Affiliation>Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical Bioengineering, University of Medicine and Pharmacy "Grigore T. Popa" Iasi, 700454 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anghelescu</LastName><ForeName>Aurelian</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8055-0541</Identifier><AffiliationInfo><Affiliation>Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Midwifery and Nursing, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popescu</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoica</LastName><ForeName>Simona-Isabelle</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Midwifery and Nursing, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aurelian</LastName><ForeName>Sorina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3215-8892</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gerontology and Geriatrics Clinic Division, St. Luca Hospital for Chronic Illnesses, 041915 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bălănescu</LastName><ForeName>Andra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine and Rheumatology Departments, "Sfânta Maria" Hospital, 011172 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Băetu</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciobanu</LastName><ForeName>Vlad</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Computer Science Department, Politehnica University of Bucharest, 060042 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onose</LastName><ForeName>Gelu</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-6346-8941</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>ISP4442I3Y</RegistryNumber><NameOfSubstance UI="C000596027">baricitinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001384">Azetidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001384" MajorTopicYN="N">Azetidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccination</Keyword><Keyword MajorTopicYN="N">PRISMA systematic literature review</Keyword><Keyword MajorTopicYN="N">Rituximab</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">rheumatoid arthritis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39456932</ArticleId><ArticleId IdType="pmc">PMC11508285</ArticleId><ArticleId IdType="doi">10.3390/ijms252011149</ArticleId><ArticleId IdType="pii">ijms252011149</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Codreanu C., Ionescu R., Predeteanu D., Rezus E., Parvu M., Mogosan C., Popescu C., Rednic S. Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemic. Rom. J. Rheumatol. 2020;29:101–111. doi: 10.37897/RJR.2020.3.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.37897/RJR.2020.3.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Trandafir A.I., Onose G., Munteanu C., Băila M., Saglam A.O., Mandu M., Săulescu I., Grădinaru E., Bojincă V.C. Particularities regarding Clinical-biological and Evolutive Parameters of Immune-mediated Rheumatic Diseases in Patients with COVID-19-systematic literature review. Balneo PRM Res. J. 2023;2023:562. doi: 10.12680/balneo.2023.562.</Citation><ArticleIdList><ArticleId IdType="doi">10.12680/balneo.2023.562</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraaijkamp J.J.M., Persoon A., Aurelian S., Bachmann S., Cameron I.D., Choukou M.-A., Dockery F., Eruslanova K., Gordon A.L., Grund S., et al. eHealth in Geriatric Rehabilitation: An International Survey of the Experiences and Needs of Healthcare Professionals. J. Clin. Med. 2023;12:4504. doi: 10.3390/jcm12134504.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12134504</ArticleId><ArticleId IdType="pmc">PMC10342292</ArticleId><ArticleId IdType="pubmed">37445545</ArticleId></ArticleIdList></Reference><Reference><Citation>Malek Mahdavi A., Varshochi M., Hajialilo M., Dastgiri S., Khabbazi R., Khabbazi A. Factors associated with COVID-19 and its outcome in patients with rheumatoid arthritis. Clin. Rheumatol. 2021;40:4527. doi: 10.1007/s10067-021-05830-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05830-4</ArticleId><ArticleId IdType="pmc">PMC8241410</ArticleId><ArticleId IdType="pubmed">34189674</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournia V.K., Fragoulis G.E., Mitrou P., Mathioudakis K., Tsolakidis A., Konstantonis G., Tseti I., Vourli G., Tektonidou M.G., Paraskevis D., et al. Different COVID-19 outcomes among systemic rheumatic diseases: A nation-wide cohort study. Rheumatology. 2023;62:1047–1056. doi: 10.1093/rheumatology/keac422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac422</ArticleId><ArticleId IdType="pmc">PMC9384656</ArticleId><ArticleId IdType="pubmed">35920774</ArticleId></ArticleIdList></Reference><Reference><Citation>Zargaran M., Movassaghi S., Seyyedsalehi M.S., Zendehdel K., Rostamian A. Outcomes of coronavirus disease 19 patients with a history of rheumatoid arthritis: A retrospective registry-based study in Iran. Int. J. Rheum. Dis. 2022;25:1196–1199. doi: 10.1111/1756-185X.14405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.14405</ArticleId><ArticleId IdType="pmc">PMC9538024</ArticleId><ArticleId IdType="pubmed">35920406</ArticleId></ArticleIdList></Reference><Reference><Citation>Glintborg B., Jensen D.V., Engel S., Terslev L., Pfeiffer Jensen M., Hendricks O., Østergaard M., Rasmussen S.H., Adelsten T., Colic A., et al. Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: Results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry. RMD Open. 2021;7:e001505. doi: 10.1136/rmdopen-2020-001505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001505</ArticleId><ArticleId IdType="pmc">PMC7786545</ArticleId><ArticleId IdType="pubmed">33402443</ArticleId></ArticleIdList></Reference><Reference><Citation>George M.D., Venkatachalam S., Banerjee S., Baker J.F., Merkel P.A., Gavigan K., Curtis D., Danila M.I., Curtis J.R., Nowell W.B. Concerns, Healthcare Use, and Treatment Interruptions in Patients with Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. J. Rheumatol. 2021;48:603–607. doi: 10.3899/jrheum.201017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.201017</ArticleId><ArticleId IdType="pmc">PMC8121899</ArticleId><ArticleId IdType="pubmed">33191284</ArticleId></ArticleIdList></Reference><Reference><Citation>Dernoncourt A., Schmidt J., Duhaut P., Liabeuf S., Gras-Champel V., Masmoudi K., Bennis Y., Batteux B. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database. Fundam. Clin. Pharmacol. 2021;36:199–209. doi: 10.1111/fcp.12695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/fcp.12695</ArticleId><ArticleId IdType="pmc">PMC8239613</ArticleId><ArticleId IdType="pubmed">33973280</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Iorio M., Cook C.E., Vanni K.M.M., Patel N.J., D’Silva K.M., Fu X., Wang J., Prisco L.C., Kowalski E., Zaccardelli A., et al. DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study. medRxiv. 2022 doi: 10.1101/2022.02.08.22270696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.08.22270696</ArticleId><ArticleId IdType="pmc">PMC9116968</ArticleId><ArticleId IdType="pubmed">35617780</ArticleId></ArticleIdList></Reference><Reference><Citation>Diiorio M., Kennedy K., Liew J.W., Putman M.S., Sirotich E., Sattui S.E., Foster G., Harrison C., Larché M.J., Levine M., et al. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2022;8:e002587. doi: 10.1136/rmdopen-2022-002587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002587</ArticleId><ArticleId IdType="pmc">PMC9475962</ArticleId><ArticleId IdType="pubmed">36104117</ArticleId></ArticleIdList></Reference><Reference><Citation>Isnardi C.A., Roberts K., Saurit V., Petkovic I., Báez R.M., Quintana R., Tissera Y., Ornella S., DAngelo-Exeni M.E., Pisoni C.N., et al. Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: Data from the SAR-COVID Registry. Clin. Rheumatol. 2023;42:563. doi: 10.1007/s10067-022-06393-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06393-8</ArticleId><ArticleId IdType="pmc">PMC9535223</ArticleId><ArticleId IdType="pubmed">36201124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge E., Li Y., Wu S., Candido E., Wei X. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. PLoS ONE. 2021;16:e0258154. doi: 10.1371/journal.pone.0258154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0258154</ArticleId><ArticleId IdType="pmc">PMC8491945</ArticleId><ArticleId IdType="pubmed">34610047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekin A., Coskun B.N., Dalkilic E., Pehlivan Y. The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy. Ir. J. Med. Sci. 2023;192:1959–1973. doi: 10.1007/s11845-022-03193-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-022-03193-6</ArticleId><ArticleId IdType="pmc">PMC9579651</ArticleId><ArticleId IdType="pubmed">36258064</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Saber Batiha G., Al-Gareeb A.I., Saad H.M., Al-kuraishy H.M. COVID-19 and corticosteroids: A narrative review. Inflammopharmacology. 2022;30:1189. doi: 10.1007/s10787-022-00987-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-00987-z</ArticleId><ArticleId IdType="pmc">PMC9106274</ArticleId><ArticleId IdType="pubmed">35562628</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N., Madhira V., Hu C., Olex A.L., Bergquist T., Fitzgerald K.C., Huling J.D., Patel R.C., Singh J.A. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C) Semin. Arthritis Rheum. 2023;58:152149. doi: 10.1016/j.semarthrit.2022.152149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2022.152149</ArticleId><ArticleId IdType="pmc">PMC9729169</ArticleId><ArticleId IdType="pubmed">36516563</ArticleId></ArticleIdList></Reference><Reference><Citation>Minca D., Minca A., Ionescu C.E., Dinache O.G., Popescu C., Agache M., Enache L., Mogosan C., Codreanu C. POS1205 COVID-19 in Patients with Inflammatory Rheumatic Diseases—Data from the Romanian Registry of Rheumatic Diseases. Ann. Rheum. Dis. 2022;81((Suppl. 1)):931. doi: 10.1136/annrheumdis-2022-eular.961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-eular.961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournia V.K., Fragoulis G.E., Mitrou P., Mathioudakis K., Konstantonis G., Tektonidou M.G., Tsolakidis A., Paraskevis D., Sfikakis P.P. Outcomes of COVID-19 Omicron variant in patients with rheumatoid arthritis: A nationwide Greek cohort study. Rheumatology. 2024;63:1130. doi: 10.1093/rheumatology/kead354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kead354</ArticleId><ArticleId IdType="pmc">PMC10986801</ArticleId><ArticleId IdType="pubmed">37467059</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonek K., Roszkowski L., Massalska M., Maslinski W., Ciechomska M. Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells. 2021;10:323. doi: 10.3390/cells10020323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020323</ArticleId><ArticleId IdType="pmc">PMC7914976</ArticleId><ArticleId IdType="pubmed">33557301</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattui S.E., Liew J.W., Kennedy K., Sirotich E., Putman M., Moni T.T., Akpabio A., Alpízar-Rodríguez D., Berenbaum F., Bulina I., et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021;7:e001814. doi: 10.1136/rmdopen-2021-001814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001814</ArticleId><ArticleId IdType="pmc">PMC8424419</ArticleId><ArticleId IdType="pubmed">34493645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T., Wang B., Shen J., Wei Y., Zhu Y., Tian X., Wen G., Xu B., Fu C., Xie Z., et al. Third dose of anti-SARS-CoV-2 inactivated vaccine for patients with RA: Focusing on immunogenicity and effects of RA drugs. Front. Med. 2022;9:978272. doi: 10.3389/fmed.2022.978272.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.978272</ArticleId><ArticleId IdType="pmc">PMC9470915</ArticleId><ArticleId IdType="pubmed">36117981</ArticleId></ArticleIdList></Reference><Reference><Citation>Jyssum I., Kared H., Tran T.T., Tveter A.T., Provan S.A., Sexton J., Jørgensen K.K., Jahnsen J., Kro G.B., Warren D.J., et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: A prospective, cohort study. Lancet Rheumatol. 2022;4:e177–e187. doi: 10.1016/S2665-9913(21)00394-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00394-5</ArticleId><ArticleId IdType="pmc">PMC8700278</ArticleId><ArticleId IdType="pubmed">34977602</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels L.E., Ammitzbøll C., Andersen J.B., Vils S.R., Mistegaard C.E., Johannsen A.D., Hermansen M.F., Thomsen M.K., Erikstrup C., Hauge E.M., et al. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol. Int. 2021;41:1925–1931. doi: 10.1007/s00296-021-04972-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04972-7</ArticleId><ArticleId IdType="pmc">PMC8412379</ArticleId><ArticleId IdType="pubmed">34476603</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveen R., Parodis I., Joshi M., Sen P., Lindblom J., Agarwal V., Lilleker J.B., Tan A.L., Nune A., Shinjo S.K., et al. COVID-19 vaccination in autoimmune diseases (COVAD) study: Vaccine safety and tolerance in rheumatoid arthritis. Rheumatology. 2023;62:2366–2376. doi: 10.1093/rheumatology/keac624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac624</ArticleId><ArticleId IdType="pubmed">36315075</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedro Engine.  [(accessed on 19 April 2024)].  Available online:  http://search.pedro.org.au/search.</Citation></Reference><Reference><Citation>Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. 2009;339:332–336. doi: 10.1136/bmj.b2535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2535</ArticleId><ArticleId IdType="pmc">PMC3090117</ArticleId><ArticleId IdType="pubmed">21603045</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., Moher D., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi: 10.1136/bmj.n160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n160</ArticleId><ArticleId IdType="pmc">PMC8005925</ArticleId><ArticleId IdType="pubmed">33781993</ArticleId></ArticleIdList></Reference><Reference><Citation>Onose G., Popescu N., Munteanu C., Ciobanu V., Sporea C., Mirea M.D., Daia C., Andone I., Spînu A., Mirea A. Mobile mechatronic/robotic orthotic devices to assist-rehabilitate neuromotor impairments in the upper limb: A systematic and synthetic review. Front. Neurosci. 2018;12:577. doi: 10.3389/fnins.2018.00577.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00577</ArticleId><ArticleId IdType="pmc">PMC6134072</ArticleId><ArticleId IdType="pubmed">30233289</ArticleId></ArticleIdList></Reference><Reference><Citation>PEDro Score—Strokengine.  [(accessed on 19 April 2024)].  Available online:  https://www.strokengine.ca/glossary/pedro--score/</Citation></Reference><Reference><Citation>PEDro Scale—PEDro.  [(accessed on 19 April 2024)].  Available online:  https://pedro.org.au/english/resources/pedro-scale/</Citation></Reference><Reference><Citation>Scott I.C., Whittle R., Bailey J., Twohig H., Hider S.L., Mallen C.D., Muller S., Jordan K.P. Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data. Lancet Reg. Health-Europe. 2022;23:100519. doi: 10.1016/j.lanepe.2022.100519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100519</ArticleId><ArticleId IdType="pmc">PMC9557034</ArticleId><ArticleId IdType="pubmed">36246147</ArticleId></ArticleIdList></Reference><Reference><Citation>Brumă E., Onose G., Ciobanu V. Research on clinical-paraclinical and evolutive aspects in patients with post spinal cord injury (SCI) statuses and COVID-19-a systematic literature review. Balneo PRM Res. J. 2023;14:538. doi: 10.12680/balneo.2023.538.</Citation><ArticleIdList><ArticleId IdType="doi">10.12680/balneo.2023.538</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezus E., Popescu C.C., Mogosan C., Avram C., Ionitescu R.C., Felea I., Filipescu I.C., Codreanu C. Treatment of rheumatoid arthritis with biologic and targeted synthetic disease-modifying anti-rheumatic drugs in 2022-real-world data from the Romanian Registry of Rheumatic Diseases CLINICAL STUDIES. Rom. J. Rheumatol. 2023;32:122–127. doi: 10.37897/RJR.2023.3.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.37897/RJR.2023.3.7</ArticleId></ArticleIdList></Reference><Reference><Citation>Saadoun D., Vieira M., Vautier M., Baraliakos X., Andreica I., da Silva J.A.P., Sousa M., Luis M., Khmelinskii N., Gracía J.M.A. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: The Euro-COVIMID multicentre cross-sectional study. Lancet Rheumatol. 2021;3:e481–e488. doi: 10.1016/S2665-9913(21)00112-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00112-0</ArticleId><ArticleId IdType="pmc">PMC8081401</ArticleId><ArticleId IdType="pubmed">33942031</ArticleId></ArticleIdList></Reference><Reference><Citation>Anghelescu A., Saglam A.O., Isabelle Stoica S., Onose G. Rehabilitation of severe neurological complications post SARS-CoV-2 infection. Balneo PRM Res. J. 2022;13:1. doi: 10.12680/balneo.2022.491.</Citation><ArticleIdList><ArticleId IdType="doi">10.12680/balneo.2022.491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu C.E., Popescu C.C., Agache M., Dinache G., Codreanu C. Depression in Rheumatoid Arthritis: Prevalence and Effects on Disease Activity. J. Clin. Med. 2024;13:2058. doi: 10.3390/jcm13072058.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13072058</ArticleId><ArticleId IdType="pmc">PMC11012436</ArticleId><ArticleId IdType="pubmed">38610822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu R. Esențialul în Reumatologie, Ediția a 3-a. Editura Amaltea; Bucharest, Romania: 2022. pp. 329–344.</Citation></Reference><Reference><Citation>Vlădulescu-Trandafir A.I., Onose G., Munteanu C., Iancu I., Bălănescu A.R., Opriș-Belinski D., Berghea F., Prefac C., Grădinaru E., Aurelian S., et al. Unraveling the Impact of COVID-19 on Rheumatoid Arthritis: Insights from Two Romanian Hospitals—Preliminary Results. Biomedicines. 2024;12:2145. doi: 10.3390/biomedicines12092145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines12092145</ArticleId><ArticleId IdType="pmc">PMC11430409</ArticleId><ArticleId IdType="pubmed">39335658</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Chen J., Ruan X., Vithayathil M., Kar S., Li X., Mason A.M., Burgess S., Larsson S.C. Rheumatoid arthritis and risk of site-specific cancers: Mendelian randomization study in European and East Asian populations. Arthritis Res. Ther. 2022;24:270. doi: 10.1186/s13075-022-02970-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-022-02970-z</ArticleId><ArticleId IdType="pmc">PMC9746148</ArticleId><ArticleId IdType="pubmed">36514134</ArticleId></ArticleIdList></Reference><Reference><Citation>Simion L., Rotaru V., Cirimbei C., Gales L., Stefan D.C., Ionescu S.O., Luca D., Doran H., Chițoran E. Inequities in Screening and HPV Vaccination Programs and Their Impact on Cervical Cancer Statistics in Romania. Diagnostics. 2023;13:2776. doi: 10.3390/diagnostics13172776.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics13172776</ArticleId><ArticleId IdType="pmc">PMC10486539</ArticleId><ArticleId IdType="pubmed">37685314</ArticleId></ArticleIdList></Reference><Reference><Citation>Chițoran E., Rotaru V., Mitroiu M.N., Durdu C.E., Bohiltea R.E., Ionescu S.O., Gelal A., Cirimbei C., Alecu M., Simion L. Navigating Fertility Preservation Options in Gynecological Cancers: A Comprehensive Review. Cancers. 2024;16:2214. doi: 10.3390/cancers16122214.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers16122214</ArticleId><ArticleId IdType="pmc">PMC11201795</ArticleId><ArticleId IdType="pubmed">38927920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., Gasparyan A.Y., Zimba O., Kitas G.D., Yessirkepov M. Interplay of diabetes mellitus and rheumatic diseases amidst the COVID-19 pandemic: Influence on the risk of infection, outcomes, and immune responses. Clin. Rheumatol. 2022;41:3897–3913. doi: 10.1007/s10067-022-06365-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06365-y</ArticleId><ArticleId IdType="pmc">PMC9458477</ArticleId><ArticleId IdType="pubmed">36076125</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier K., Genin M., Jean T.P., Avouac J., Flipo R.M., Georgin-Lavialle S., El Mahou S., Pertuiset E., Pham T., Servettaz A., et al. CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases. Front. Med. 2023;10:1152587. doi: 10.3389/fmed.2023.1152587.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1152587</ArticleId><ArticleId IdType="pmc">PMC10075312</ArticleId><ArticleId IdType="pubmed">37035330</ArticleId></ArticleIdList></Reference><Reference><Citation>Scirocco C., Ferrigno S., Andreoli L., Fredi M., Lomater C., Moroni L., Mosca M., Raffeiner B., Carrara G., Landolfi G., et al. COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: Results from the CONTROL-19 Study by the Italian Society for Rheumatology. Lupus Sci. Med. 2023;10:e000945. doi: 10.1136/lupus-2023-000945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2023-000945</ArticleId><ArticleId IdType="pmc">PMC10582885</ArticleId><ArticleId IdType="pubmed">37848262</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Zheng Q., Madhira V., Olex A.L., Anzalone A.J., Vinson A., Singh J.A., French E., Abraham A.G., Mathew J., et al. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection after SARS-CoV-2 Vaccination in the US. JAMA Intern. Med. 2022;182:153–162. doi: 10.1001/jamainternmed.2021.7024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.7024</ArticleId><ArticleId IdType="pmc">PMC8715386</ArticleId><ArticleId IdType="pubmed">34962505</ArticleId></ArticleIdList></Reference><Reference><Citation>Munteanu C., Rotariu M., Turnea M.A., Anghelescu A., Albadi I., Dogaru G., Silișteanu S.C., Ionescu E.V., Firan F.C., Ionescu A.M., et al. Topical Reappraisal of Molecular Pharmacological Approaches to Endothelial Dysfunction in Diabetes Mellitus Angiopathy. Curr. Issues Mol. Biol. 2022;44:3378. doi: 10.3390/cimb44080233.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cimb44080233</ArticleId><ArticleId IdType="pmc">PMC9406839</ArticleId><ArticleId IdType="pubmed">36005129</ArticleId></ArticleIdList></Reference><Reference><Citation>Berghea F., Berghea C.E., Zaharia D., Trandafir A.I., Nita E.C., Vlad V.M. Residual Pain in the Context of Selecting and Switching Biologic Therapy in Inflammatory Rheumatic Diseases. Front. Med. 2021;8:712645. doi: 10.3389/fmed.2021.712645.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.712645</ArticleId><ArticleId IdType="pmc">PMC8415826</ArticleId><ArticleId IdType="pubmed">34485342</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornero C., Pastor E., Garzando M.d.M., Orduña J., Forner M.J., Bocigas I., Cedeño D.L., Vallejo R., McClure C.K., Czura C.J., et al. Non-invasive Vagus Nerve Stimulation for COVID-19: Results From a Randomized Controlled Trial (SAVIOR I) Front. Neurol. 2022;13:820864. doi: 10.3389/fneur.2022.820864.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.820864</ArticleId><ArticleId IdType="pmc">PMC9028764</ArticleId><ArticleId IdType="pubmed">35463130</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedeschi S.K., Ellrodt J., Stratton J., Santacroce L., Chandler P.D., Gravallese E.M., Solomon D.H. Acceptability of Vaccines against Preventable Infections Including Coronavirus Disease 2019 Among Patients with Rheumatic Disease. ACR Open Rheumatol. 2022;4:3–7. doi: 10.1002/acr2.11351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11351</ArticleId><ArticleId IdType="pmc">PMC8652709</ArticleId><ArticleId IdType="pubmed">34613668</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinelli F.R., Favalli E.G., Garufi C., Cornalba M., Colafrancesco S., Conti F., Caporali L. Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. Arthritis Res. Ther. 2022;24:1–8. doi: 10.1186/s13075-021-02674-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02674-w</ArticleId><ArticleId IdType="pmc">PMC8748531</ArticleId><ArticleId IdType="pubmed">35016701</ArticleId></ArticleIdList></Reference><Reference><Citation>Eerike M., Parimi V.P., M D., Pyati A., Sundaramurthy R., Sakthivadivel V., Pidugu A.B., Pharm D., Surapareddy B., Ramineni N.T., et al. Clinical and immunological responses to COVID-19 vaccination in rheumatoid arthritis patients on disease modifying antirheumatic drugs: A cross-sectional study. J. Rheum. Dis. 2024;31:15. doi: 10.4078/jrd.2023.0054.</Citation><ArticleIdList><ArticleId IdType="doi">10.4078/jrd.2023.0054</ArticleId><ArticleId IdType="pmc">PMC10730806</ArticleId><ArticleId IdType="pubmed">38130958</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordtz R., Kristensen S., Westermann R., Duch K., Pearce F., Lindhardsen J., Torp-Pedersen C., Andersen M.P., Dreyer L. COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis. Rheumatology. 2022;62:77–88. doi: 10.1093/rheumatology/keac241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac241</ArticleId><ArticleId IdType="pmc">PMC9047209</ArticleId><ArticleId IdType="pubmed">35416949</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleem B., Ross R.L., Bissell L.A., Aslam A., Mankia K., Duquenne L., Corsadden D., Carter C., Hughes P., Nadat F.A., et al. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: As determined by antibody and T cell responses. RMD Open. 2022;8:e002050. doi: 10.1136/rmdopen-2021-002050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-002050</ArticleId><ArticleId IdType="pmc">PMC8977455</ArticleId><ArticleId IdType="pubmed">35365569</ArticleId></ArticleIdList></Reference><Reference><Citation>Md Yusof M.Y., Arnold J., Saleem B., Vandevelde C., Dass S., Savic S., Vital E.M., Emery P. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: A single-centre cohort study. Lancet Rheumatol. 2023;5:e88–e98. doi: 10.1016/S2665-9913(23)00004-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(23)00004-8</ArticleId><ArticleId IdType="pmc">PMC9873269</ArticleId><ArticleId IdType="pubmed">36712951</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhishek A., Boyton R.J., Peckham N., McKnight Á., Coates L.C., Bluett J., Barber V., Cureton L., Francis A., Appelbe D., et al. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): A randomised, open label, superiority trial. Lancet Respir. Med. 2022;10:840–850. doi: 10.1016/S2213-2600(22)00186-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00186-2</ArticleId><ArticleId IdType="pmc">PMC9236568</ArticleId><ArticleId IdType="pubmed">35772416</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaria T.G., Sreeprakash A., Umesh R., Joseph S., Mohan M., Ahmed S., Mehta P., Oommen S.E., Benny J., Paulose A., et al. Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): Results of two, parallel, assessor-masked, randomised controlled trials. Lancet Rheumatol. 2022;4:e755–e764. doi: 10.1016/S2665-9913(22)00228-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00228-4</ArticleId><ArticleId IdType="pmc">PMC9612848</ArticleId><ArticleId IdType="pubmed">36320825</ArticleId></ArticleIdList></Reference><Reference><Citation>Farroni C., Picchianti-Diamanti A., Aiello A., Nicastri E., Laganà B., Agrati C., Castilletti C., Meschi S., Colavita F., Cuzzi G., et al. Kinetics of the B- and T-Cell Immune Responses after 6 Months From SARS-CoV-2 mRNA Vaccination in Patients with Rheumatoid Arthritis. Front Immunol. 2022;13:846753. doi: 10.3389/fimmu.2022.846753.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.846753</ArticleId><ArticleId IdType="pmc">PMC8924958</ArticleId><ArticleId IdType="pubmed">35309297</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Li F., Tian J., Xie X., Tang Q., Chen Y., Ge Y. Varicella zoster virus reactivation following COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: A cross-sectional Chinese study of 318 cases. J. Med. Virol. 2023;95:e28307. doi: 10.1002/jmv.28307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28307</ArticleId><ArticleId IdType="pmc">PMC9878204</ArticleId><ArticleId IdType="pubmed">36372774</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakafero G., Grainge M.J., Card T., Mallen C.D., Nguyen Van-Tam J.S., Williams H.C., Abhishek A. Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis. Rheumatology. 2023;62:1445–1450. doi: 10.1093/rheumatology/keac484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac484</ArticleId><ArticleId IdType="pmc">PMC10070057</ArticleId><ArticleId IdType="pubmed">36048896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri C., Ursini F., Gragnani L., Raimondo V., Giuggioli D., Foti R., Caminiti M., Olivo D., Cuomo G., Visentini M., et al. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups. J. Autoimmun. 2021;125:102744. doi: 10.1016/j.jaut.2021.102744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102744</ArticleId><ArticleId IdType="pmc">PMC8577991</ArticleId><ArticleId IdType="pubmed">34781162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandinelli F., Pagano M., Vallecoccia M.S. Post-COVID-19 and Post-COVID-19 Vaccine Arthritis, Polymyalgia Rheumatica and Horton’s Arteritis: A Single-Center Assessment of Clinical, Serological, Genetic, and Ultrasonographic Biomarkers. J. Clin. Med. 2023;12:7563. doi: 10.3390/jcm12247563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12247563</ArticleId><ArticleId IdType="pmc">PMC10743539</ArticleId><ArticleId IdType="pubmed">38137631</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng K., Li X., Yang D., Chan S.C.W., Zhou J., Wan E.Y.F., Chui C.S.L., Lai F.T.T., Wong C.K.H., Chan E.W.Y., et al. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: A population-based cohort study. EClinicalMedicine. 2023;63:102154. doi: 10.1016/j.eclinm.2023.102154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102154</ArticleId><ArticleId IdType="pmc">PMC10458663</ArticleId><ArticleId IdType="pubmed">37637754</ArticleId></ArticleIdList></Reference><Reference><Citation>Picchianti-Diamanti A., Aiello A., Laganà B., Agrati C., Castilletti C., Meschi S., Farroni C., Lapa D., Najafi-Fard S., Cuzzi G., et al. ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. Front. Immunol. 2021;12:740249. doi: 10.3389/fimmu.2021.740249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.740249</ArticleId><ArticleId IdType="pmc">PMC8477040</ArticleId><ArticleId IdType="pubmed">34594343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammam N., Mosad D., Ibrahim A.M., Abdel-Fattah Y.H., Aly H.M., El-Saadany H.M., Nassr M., Moshrif A., Fathi H.M. Safety of Vaccination against Coronavirus Disease-19 (COVID-19) in Rheumatic and Musculoskeletal Diseases (Rmds) Patients: Results from the (ECR)-COVID-19 Group. Oman Med. J. 2024 doi: 10.5001/omj.2024.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.5001/omj.2024.107</ArticleId></ArticleIdList></Reference><Reference><Citation>Medeiros-Ribeiro A.C., Bonfiglioli K.R., Domiciano D.S., Shimabuco A.Y., Da Silva H.C., Saad C.G.S., Yuki E.F.N., Pasoto S.G., Araujo C.S.R., Nakai T.L., et al. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. Ann. Rheum. Dis. 2022;81:710–719. doi: 10.1136/annrheumdis-2021-221735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221735</ArticleId><ArticleId IdType="pubmed">35135832</ArticleId></ArticleIdList></Reference><Reference><Citation>Schäfer A., Kovacs M.S., Eder A., Nigg A., Feuchtenberger M. TNF inhibitors significantly attenuate the humoral immune response to COVID-19 vaccination in patients with rheumatoid arthritis. Rheumatol. Adv. Pract. 2023;7:rkad065. doi: 10.1093/rap/rkad065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rap/rkad065</ArticleId><ArticleId IdType="pmc">PMC10406699</ArticleId><ArticleId IdType="pubmed">37560623</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Liu S., Han J., Li S., Gao X., Wang M., Zhu J., Jin T. Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems. Front. Immunol. 2021;12:777606. doi: 10.3389/fimmu.2021.777606.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.777606</ArticleId><ArticleId IdType="pmc">PMC8591135</ArticleId><ArticleId IdType="pubmed">34790205</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta D., Nagappa M., Sreekumaran Nair B.V., Das S.K., Wahatule R., Sinha S., Vasanthapuram R., Taly A.B., Debnath M. Variations within Toll-like receptor (TLR) and TLR signaling pathway-related genes and their synergistic effects on the risk of Guillain-Barré syndrome. J. Peripher. Nerv. System. 2022;27:131–143. doi: 10.1111/jns.12484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jns.12484</ArticleId><ArticleId IdType="pubmed">35138004</ArticleId></ArticleIdList></Reference><Reference><Citation>Klatka M., Polak A., Mertowska P., Mertowski S., Łyczba J., Hymos A., Korona-Głowniak I., Grywalska E. The Role of Toll-like Receptor 2 (TLR2) in the Development and Progression of Hashimoto’s Disease (HD): A Case Study on Female Patients in Poland. Int. J. Mol. Sci. 2023;24:5344. doi: 10.3390/ijms24065344.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24065344</ArticleId><ArticleId IdType="pmc">PMC10049147</ArticleId><ArticleId IdType="pubmed">36982416</ArticleId></ArticleIdList></Reference><Reference><Citation>Arévalo-Cortés A., Rodriguez-Pinto D., Aguilar-Ayala L. Evidence for Molecular Mimicry between SARS-CoV-2 and Human Antigens: Implications for Autoimmunity in COVID-19. Autoimmune Dis. 2024;2024:8359683. doi: 10.1155/2024/8359683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2024/8359683</ArticleId><ArticleId IdType="pmc">PMC11380714</ArticleId><ArticleId IdType="pubmed">39247752</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M., Herrán M., Ramírez-Santana C., Leung P.S.C., Anaya J.M., Ridgway W.M., Gershwin M.E. Molecular mimicry and autoimmunity in the time of COVID-19. J. Autoimmun. 2023;139:103070. doi: 10.1016/j.jaut.2023.103070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2023.103070</ArticleId><ArticleId IdType="pmc">PMC10258587</ArticleId><ArticleId IdType="pubmed">37390745</ArticleId></ArticleIdList></Reference><Reference><Citation>Churilov L.P., Normatov M.G., Utekhin V.J. Molecular Mimicry between SARS-CoV-2 and Human Endocrinocytes: A Prerequisite of Post-COVID-19 Endocrine Autoimmunity? Pathophysiology. 2022;29:486. doi: 10.3390/pathophysiology29030039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathophysiology29030039</ArticleId><ArticleId IdType="pmc">PMC9504401</ArticleId><ArticleId IdType="pubmed">36136066</ArticleId></ArticleIdList></Reference><Reference><Citation>Felipe Cuspoca A., Isaac Estrada P., Velez-van-Meerbeke A. Molecular Mimicry of SARS-CoV-2 Spike Protein in the Nervous System: A Bioinformatics Approach. Comput. Struct. Biotechnol. J. 2022;20:6041. doi: 10.1016/j.csbj.2022.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2022.10.022</ArticleId><ArticleId IdType="pmc">PMC9605789</ArticleId><ArticleId IdType="pubmed">36317085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>